The American Journal of Medicine
Volume 121, Issue 7, Supplement 2 , Pages S22-S27 , July 2008

Lessons Learned: Role of Influenza Vaccine Production, Distribution, Supply, and Demand—What It Means for the Provider

  • Walter A. Orenstein, MD

      Affiliations

    • Emory Vaccine Center, Atlanta, Georgia, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Walter A. Orenstein, MD, Emory Vaccine Center, 1462 Clifton Road NE, Suite 446, Atlanta, Georgia 30322.
    • ,
  • William Schaffner, MD

      Affiliations

    • Departments of Preventive Medicine and Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

References 

  1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186
  2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333–1340
  3. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep. 2007;56(RR06):1–54
  4. Centers for Disease Control and Prevention (CDC). CDC's advisory committee recommends influenza vaccination for children 6 months through 18 years of age [press release]. http://www.cdc.gov/media/pressrel/2008/r080227.htmAccessed May 29, 2008
  5. Mason D. A vaccine supply update for the US marketPresented at the National Vaccine Advisory Committee Meeting; Washington, DC: June 3, 2003 [PowerPoint slide presentation]. www.hhs.gov/nvpo/meetings/jun2003/mason-s.pptAccessed February 22, 2008
  6. Orenstein WA, Douglas RG, Rodewald LE, Hinman AR. Immunizations in the United States: success, structure, and stress. Health Aff (Millwood). 2005;24:599–610
  7. Layton C, Robinson T, Honeycutt A. Influenza Vaccine Demand: The Chicken and the Egg, Issue Brief, 2005. Prepared for the Assistant Secretary for Planning and Evaluation, US Dept of Health and Human Services, under Contract No. 100-03-0001 [report]. Research Triangle Park, NC: RTI International. RTI Project No. 0208665.001 http://aspe.hhs.gov/pic/fullreports/06/8476-4.docAccessed March 6, 2008
  8. Rodewald LE, Orenstein WA, Mason DD, Cochi SL. Vaccine supply problems: a perspective of the Centers for Disease Control and Prevention. Clin Infect Dis. 2006;42(suppl 3):S104–S110
  9. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2002;51(RR03):1–31
  10. Danzon PM, Pereira NS, Tejwani SS. Vaccine supply: a cross-national perspective. Health Aff (Millwood). 2005;24:706–717
  11. Gerberding JL. US influenza supply and preparations for the future (Testimony before the Committee on Government Reform, US House of Representatives). February 10, 2005. http://www.hhs.gov/asl/testify/t050210b.htmlAccessed.
  12. Fishbein DB, Fontanesi J, Kopald D, et al. Why do not patients receive influenza vaccine in December and January?. Vaccine. 2006;24:798–802
  13. Fiore A. Influenza activity in the United States, February 2007. Presented at the Advisory Committee on Immunization Practices, October 23, 2007, Atlanta, Georgia http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-Oct07/93-flu.pdfAccessed May 28, 2008
  14. US Department of Health and Human Services. Healthy People 2010 influenza immunization goals. http://www.healthypeople.gov/document/html/objectives/14-29.htmAccessed March 5, 2008
  15. Coleman M, Sangrujee N, Zhou F, Chu S. Factors affecting US manufacturers' decision to produce vaccines. Health Aff (Millwood). 2005;24:635–642
  16. Betts RF. Influenza virus. In:  Mandell GL,  Bennett JE,  Dolin R editor. Mandell, Douglass, and Bennett's Principles and Practice of Infectious Diseases. 4th ed.. New York: Churchill Livingstone; 1994;p. 1546–1567
  17. Layton C, Lenfestey N. Influenza Vaccine Manufacturing, Issue Brief, October 2005. Prepared for the Assistant Secretary for Planning and Evaluation, US Dept of Health and Human Services, under Contract No. 100-03-0001 [report]. Research Triangle Park, NC: RTI International. RTI Project No. 0208665.001 http://aspe.hhs.gov/pic/fullreports/06/8476-2.docAccessed March 6, 2008
  18. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284:1655–1663
  19. Bridges CB, Katz JM, Levandowski RA, Cox NJ. Inactivated influenza vaccines. In:  Plotkin SA,  Orenstein WA,  Offit PA editor. Vaccines. 5th ed.. Philadelphia: Elsevier; 2008;p. 259–290
  20. Belshe RB, Walker R, Stoddard J, et al. Influenza vaccine-live. In:  Plotkin SA,  Orenstein WA,  Offit PA editor. Vaccines. 5th ed.. Philadelphia: Elsevier; 2008;p. 291–309
  21. Wallace GS. Vaccine supply update & programmatic implications. Presented at the Advisory Committee on Immunization Practices, February 27, 2008; Atlanta [PowerPoint slide presentation] http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-feb08/23-vac-supply.pdfAccessed May 28, 2008
  22. Jones TF, Ingram LA, Craig AS, Schaffner W. Determinants of influenza vaccination, 2003-2004: shortages, fallacies and disparities. Clin Infect Dis. 2004;39:1824–1828
  23. Hinman AR, Orenstein WA, Rodewald L. Financing immunizations in the United States. Clin Infect Dis. 2004;38:1440–1446
  24. Institute of Medicine. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: The National Academies Press; 2003;http://www.iom.edu/?id=14451&redirect=0Accessed March 5, 2008
  25. Adler GS. Influenza vaccination and self-reported reasons for not receiving influenza vaccination among Medicare beneficiaries aged ≥65 years: United States, 1991-2002. MMWR Morb Mortal Wkly Rep. 2004;53:1012–1015
  26. Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine. 2005;23:2251–2255
  27. National Influenza Vaccine Summit. Minutes of meeting; January 24-25, 2006; Atlanta, GA. http://www.ama-assn.org/ama1/pub/upload/mm/36/summit_minutes.pdfAccessed March 5, 2008
  28. Belshe RB. Translational research on vaccines: influenza as an example. Clin Pharmacol Ther. 2007;82:745–749
  29. Cox MM. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther. 2008;10:56–61
  30. Abramson JS, Neuzil KM, Tamblyn SE. Annual universal influenza vaccination: ready or not?. Clin Infect Dis. 2006;42:132–135

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00467-1

doi: 10.1016/j.amjmed.2008.05.004

The American Journal of Medicine
Volume 121, Issue 7, Supplement 2 , Pages S22-S27 , July 2008

Article Tools

* Image Usage & Resolution